BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34743547)

  • 1. A summertime pause in immunoglobulin replacement therapy: a prospective real-world analysis.
    Hémar V; Rivière E; Greib C; Machelart I; Roucoules M; Prot C; Pellegrin JL; Viallard JF; Lazaro E
    Immunotherapy; 2021 Dec; 13(18):1491-1499. PubMed ID: 34743547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of octagam and gammanorm in immunodeficiency associated with hematological malignancies: a prospective study from 21 French hematology departments.
    Benbrahim O; Viallard JF; Choquet S; Royer B; Bauduer F; Decaux O; Crave JC; Fardini Y; Clerson P; Lévy V
    Hematology; 2019 Dec; 24(1):173-182. PubMed ID: 30458690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced risk of infections with the intravenous immunoglobulin, IgPro10, in patients at risk of secondary immunodeficiency-related infections.
    Lahue BJ; Mallick R; Zhang X; Heidt J; Song Y; Koenig AS; Espinoza G
    Immunotherapy; 2022 Oct; 14(15):1245-1261. PubMed ID: 35971794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A French observational study describing the use of human polyvalent immunoglobulins in hematological malignancy-associated secondary immunodeficiency.
    Benbrahim O; Viallard JF; Choquet S; Royer B; Bauduer F; Decaux O; Crave JC; Fardini Y; Clerson P; Lévy V
    Eur J Haematol; 2018 Jul; 101(1):48-56. PubMed ID: 29644723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies.
    Na IK; Buckland M; Agostini C; Edgar JDM; Friman V; Michallet M; Sánchez-Ramón S; Scheibenbogen C; Quinti I
    Eur J Haematol; 2019 Jun; 102(6):447-456. PubMed ID: 30801785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization of intravenous or subcutaneous immunoglobulins in secondary immune deficiency (ULTIMATE): A retrospective multicenter study.
    Legendre P; Chahwan D; Marjanovic Z; Vignon M; Hermine O; Lortholary O; Morelle G; Darrodes M; Kahn JE; Ouzegdouh M; Chaibi P; Montestruc F; Caumont-Prim A; Le Jouan M; Hassani Y; Godeau B; Durand-Zaleski I; Mouthon L
    Clin Immunol; 2020 Jun; 215():108419. PubMed ID: 32289463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infections in secondary immunodeficiency patients treated with Privigen
    Mallick R; Divino V; Smith BD; Jolles S; DeKoven M; Vinh DC
    Leuk Lymphoma; 2021 Dec; 62(14):3463-3473. PubMed ID: 34569910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoglobulin use in immune deficiency in the UK: a report of the UKPID and National Immunoglobulin Databases.
    Shillitoe B; Hollingsworth R; Foster M; Garcez T; Guzman D; Edgar JD; Buckland M
    Clin Med (Lond); 2018 Oct; 18(5):364-370. PubMed ID: 30287427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk Factors of Pneumonia in Primary Antibody Deficiency Patients Receiving Immunoglobulin Therapy: Data from the US Immunodeficiency Network (USIDNET).
    Syed MN; Kutac C; Miller JM; Marsh R; Sullivan KE; Cunningham-Rundles C; Fuleihan RL; Kheradmand F; Hajjar J
    J Clin Immunol; 2022 Oct; 42(7):1545-1552. PubMed ID: 35779201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort "Visages".
    Bienvenu B; Cozon G; Hoarau C; Pasquet M; Cherin P; Clerson P; Hachulla E; Crave JC; Delain JC; Jaussaud R
    Orphanet J Rare Dis; 2016 Jun; 11(1):83. PubMed ID: 27334100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of immunoglobulin replacement therapy in patients with secondary antibody deficiency in daily practice: a European expert Q&A-based review.
    Cinetto F; Francisco IE; Fenchel K; Scarpa R; Montefusco V; Pluta A; Wolf HM
    Expert Rev Hematol; 2023 Apr; 16(4):237-243. PubMed ID: 37009667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Facilitated subcutaneous immunoglobulin use in pediatric patients with primary or secondary immunodeficiency diseases.
    Baumann U; Fasshauer M; Pausch C; Wittkowski H; Hermann C; Pittrow D; Borte M
    Immunotherapy; 2022 Feb; 14(2):135-143. PubMed ID: 34743590
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency.
    Windegger TM; Nghiem S; Nguyen KH; Fung YL; Scuffham PA
    Vox Sang; 2019 Apr; 114(3):237-246. PubMed ID: 30883804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Evidence of Tolerability of 20% Subcutaneous Immunoglobulin Treatment.
    Rosenbach K; Park M; Sanchirico M; Nwose O; Paris K
    J Clin Immunol; 2023 Jul; 43(5):912-920. PubMed ID: 36809598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic literature review of the effects of immunoglobulin replacement therapy on the burden of secondary immunodeficiency diseases associated with hematological malignancies and stem cell transplants.
    Monleón Bonet C; Waser N; Cheng K; Tzivelekis S; Edgar JDM; Sánchez-Ramón S
    Expert Rev Clin Immunol; 2020 Sep; 16(9):911-921. PubMed ID: 32783541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discontinuation of immunoglobulin replacement therapy in patients with secondary antibody deficiency.
    Patel V; Cowan J
    Expert Rev Clin Immunol; 2020 Jul; 16(7):711-716. PubMed ID: 32588670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral Immunodeficiency and Immune Globulin Replacement Therapy (IGRT) Usage in DiGeorge Syndrome.
    Soshnick SH; Joseph T; Bennett NJ
    J Clin Immunol; 2021 Aug; 41(6):1208-1212. PubMed ID: 33740168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Replacement therapy with subcutaneous immunoglobulin in primary immunodeficiency in children].
    Pac M
    Pol Merkur Lekarski; 2011 Jun; 30(180):413-6. PubMed ID: 21751550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoglobulin Replacement Therapy for Primary Immunodeficiency.
    Sriaroon P; Ballow M
    Immunol Allergy Clin North Am; 2015 Nov; 35(4):713-30. PubMed ID: 26454315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab and immune deficiency: case series and review of the literature.
    Kaplan B; Kopyltsova Y; Khokhar A; Lam F; Bonagura V
    J Allergy Clin Immunol Pract; 2014; 2(5):594-600. PubMed ID: 25213054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.